KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.

Kenichi Harano, Roldano Fossati, Beatriz Pardo, Francesca Galli, Emma Hudson, Yoland Antill, Chulmin Lee, Manuela Rabaglio, Florian Heitz, Vassiliki Kolovetsiou-Kreiner, Chyong-Huey Lai, Elena Biagioli, Luis Manso, Shin Nishio, Karen Allan, Yeh Chen Lee, Sara Uggeri, Andres Redondo, Satoshi Nakagawa, Eunice Au, Janine Lombard, Angiolo Gadducci, Kazuhiro Takehara, Edi Editta Baldini, Innocenza Palaia, Claudia Casanova, Antonio Ardizzoia, Alessandra Bologna, Maria-Pilar Barretina-Ginesta, Nicoletta Colombo

J Gynecol Oncol 36(4) e117

PMID40590326
PMCIDPMC12226327
DOI10.3802/jgo.2025.36.e117
发表日期2025-07-01
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

OBJECTIVE: This post-hoc analysis of the AtTEnd trial explored differences in the prognostic characteristics and in the efficacy of atezolizumab between Asians and non-Asians. METHODS: The role of Asian race was evaluated on progression-free survival (PFS) using Cox-models and on time to appearance of new lesions using Fine and Gray models. RESULTS: From October 2018 to February 2022, 549 patients were randomized, of whom, 20.4% were Asian. Asians showed a better prognostic profile in terms of age, body mass index, Eastern Cooperative Oncology Group performance status, disease status and previous treatments. The prognostic impact of Asian race on PFS was confirmed in the placebo arm (adjusted hazard ratio [HR]=0.41; 95% confidence interval [CI]=0.24-0.70). In proficient mismatch repair (pMMR) tumors, the HRs for PFS comparing atezolizumab versus placebo were 0.82 (95% CI=0.63-1.05) in non-Asians, and 1.42 (95% CI=0.80-2.50) in Asians. In the pMMR population randomized to atezolizumab, the subdistribution HRs comparing Asians to non-Asians were 0.68 (95% CI=0.43-1.09) for progression with new lesions and 1.21 (95% CI=0.73-2.03) for progression without new lesions. Asians showed a higher occurrence of severe adverse events in atezolizumab compared to placebo arm (Asians: 82.1% vs. 64.3%, p=0.036; non-Asian: 63.3% vs. 63.6%, p=0.949). CONCLUSION: Race seems to affect the safety of the addition of atezolizumab and, in pMMR tumors, also its efficacy. In the atezolizumab arm, Asian patients seem to have a lower cumulative incidence of new lesions when primary tumor regrowth was considered a competing risk, and a higher cumulative incidence of primary tumor regrowth when new lesions appearance was the competing risk. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03603184.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2

Fig. 2. Kaplan-Meier curves of PFS according to treatment arm and race. (A) dMMR subgroup and (B) pMMR subgroup. CI, confidence interval; dMMR, deficient mismatch repair; PFS, progression-free survival; pMMR, proficient mismatch repair.

A

PFS

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Flow chart of the study population. dMMR, deficient mismatch repair; ITT, intention-to-treat; MMR, mismatch repair; pMMR, proficient mismatch repair.
非 KM Figure
Fig. 3Fig. 3. Cumulative incidence curves of progression. Cumulative incidence curves of progression for (A) new lesions, (B) tumor regrowth in placebo arm according to race; cumulative incidence curves of progression for (C) new lesions, (D) tumor regrowth in atezolizumab arm according to race.
非 KM Figure